Two senior executives formerly at mRNA specialist BioNTech have lifted the curtain on a new biotech called Bios Life that they call "an AI-native cancer surveillance company." Meanwhile, Zach Taylor, formerly a senior vice president at BioNTech, is taking on the role of chief operating officer. Bios Life intends to develop a virtual clinic that offers a personalised and continuous approach to cancer screening and care, including cancer survivors and high-risk individuals, in what it calls a "new category of cancer care." "Tens of millions of high-risk individuals and cancer survivors lack access to cutting-edge care [...] tailored to their particular needs and their unique biology," said Richardson. Given that one out of every five newly diagnosed cancers in the US is found in cancer survivors, use of an AI-enhanced care model promises to "move us from stagnation to the long-promised potential of personalised and precise cancer screening."